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Abstract. Background/Aim: Exposure of organs at risk with
prostate radiotherapy (RT) is lower in the prone position. This
study is a prospective evaluation of setup accuracy, side-
effects, and quality of life (QOL) during and after prone
positioned RT. Patients and Methods: Image-guided (IG)
intensity-modulated (IM) RT was administered in prone
position on belly-board to 55 high-risk prostate cancer (PC)
patients. Rectum diameters were measured in two areas of the
symphysis at the beginning of RT and during it. Side-effects,
QOL, and prostate specific symptoms (PSS) were evaluated.
Results: Setup accuracy was similar to that reported in the
literature. In the upper area of symphysis rectal diameters
were significantly changed during treatment, but in the
prostate region, no difference was detected. No change was
detected in patients’ QOL and PSS during treatment, but after
RT, they improved. Conclusion: Prone positioned IG-IMRT is
feasible with tolerable side-effects for high-risk PC patients.
Changes in QOL and PSS are insignificant during RT, while
improvement after RT suggests a rapid recovery.
The incidence of prostate cancer (PC) is growing in every
industrial country (1). Depending on the stage, surgical therapy,
radiotherapy, and hormonal therapy are the potential options in
the treatment of localized PC; in case of high risk cancers,
administration of androgen deprivation therapy (ADT) is
recommended simultaneously with radiotherapy (2). The sort-
term and long-term side-effects of therapy are very important
as PC patients usually have long survival (2, 3). 
The elevation of radiation dose significantly improves
biochemical control and disease-free survival independently
of the type of radiotherapy, i.e., three-dimensional conformal
radiotherapy (3DCRT), intensity-modulated radiotherapy
(IMRT), image-guided radiotherapy (IGRT) (3-5). In case of
high risk carcinoma, radiotherapy of the pelvic lymph nodes
is also possible besides radiotherapy of prostate and seminal
vesicle but may result in more severe side-effects (6). In
clinical practice, toxicity can be reduced by the use of
modern radiotherapy techniques by decreasing the safety
margins (e.g. IMRT, IGRT), by advantageous patient
positioning and with almost constant fullness of the rectum
and the urinary bladder (7, 8).
During radiotherapy the supine position is the most
frequently used laying method. Patients can be treated also in
a prone position (with the use of belly board - BB), and the use
of BB is associated with lower dose burden of intestines in
several clinical trials of pelvic cancers formerly in the 3DCRT
and nowadays in the IMRT-IGRT era (9-12), which was
confirmed in our previous study (in the process for publication)
as well. Few publications show that the use of BB is associated
with similar or better therapeutic efficiency and significantly
lower rectal dose (13, 14), but other articles suggest that the
daily positioning of patients might be more difficult (15).
Rectal- and urinary bladder walls next to the prostate receive
the highest irradiation dose; therefore, providing the constant
fullness of these organs is necessary by using standardized
bladder preparation protocol, treating patients at a fix daily
time and maintaining anti-flatulence diet (5, 8). 
Aims of the study were evaluation of daily setup accuracy,
determination of the necessary safety margins and analysis
of the patients’ quality of life and side-effects of the therapy
in case of PC patients treated with extended (with therapy of
regional lymph nodes) radiotherapy in a prone position by
IMRT-IGRT technique.
Patients and Methods
Patients. Patients with histologically-confirmed, localized or locally
advanced (T2-4 N0-1 M0) high risk (PSA>20 ng/ml or Gleason
score ≥8) PC after the multidisciplinary board’s decision and
signature of informed consent were enrolled into our prospective
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analysis (number of ethical approval: WHO3856/2016) at the
Department of Oncotherapy, University of Szeged, between
February 2016 and June 2017. Patients with permanent urinary
catheter, or who could not lie in prone position due to any co-
morbidities (e.g. hip prosthesis, dyspnoea) were excluded. All
patients received androgen deprivation therapy. Stage was
determined with standard methods (prostate specific antigen (PSA)
level, chest X-ray or computer tomography (CT), abdominal and
pelvic magnetic resonance imaging (MRI), bone scintigraphy) and
TNM 7th edition (16).
Method of radiotherapy
Patient positioning, target volumes and planning. Topometric CT
was performed in prone position with BB, All in One (AIO)
Solution (ORFIT, Wijnegem, Belgium), with individual
immobilization system and six-point thermoplastic mask fixation
(Pelvicast system, ORFIT, Wijnegem, Belgium). Polystyrene wedge
was placed between the buttocks. The patient’s skin was marked in
accordance with the laser marks. Standard bladder filling (drinking
half litter of liquid during the 30 min before CT) and keep anti-
flatulence diet for 7 days before the beginning and during the
therapy were recommended. Topometric CT was performed on a
Somatom Emotion 6 CT simulator (Siemens, Erlangen, Germany),
CT slices were acquired every 5 mm from the diaphragm to an
imaginary line 10 cm below the femoral heads. 
Target volumes (pelvic lymph nodes, seminal vesicle and
prostate) and organs at risk (OARs – bladder, rectum, bones, femur
heads, penile bulb, small and large intestine) were delineated after
MRI fusion in the ARIA Oncology Information System (Varian
Oncology Systems, Palo Alto, CA, USA) with review of an
experienced radiologist in all cases, based on the recommendations
of RTOG GU Radiation Oncology Specialists Reach Consensus
(17). For treatment planning Eclipse planning system was used
(Varian Oncology Systems). Isocentric 7 fields IMRT technique was
administered with inverse planning according to the RTOG
recommendations (17).
Image-guided radiotherapy (IGRT) and determination of safety
margins. Therapy was administered five times a week with 6 MV
photon beams to 77 Gy total doses. Treatment of patients during the
same period of the day was attempted. During therapy, online and
offline monitoring and data recording were performed by CBCT.
After determining the systematic and random errors the CTV-PTV
margin was calculated based on van Herk formula (18) (A=2.5 • Σpop
+ 0.7 • σpop). In this calculated safety zone 90% of patients received
95% of prescribed dose.
Daily evaluation of the rectal fullness. The anteroposterior (AP, 0-
180˚), the lateral (LAT, 90-270˚) and the oblique (OBL, 135-315˚)
diameters were determined in the upper and lower area of the
symphysis on the topometric CT rather than during the radiotherapy
on the CBCT in the same regions. The daily alterations of treatment
time were analysed.
Evaluation of side-effects and quality of life. Side-effects and quality
of life were evaluated based on the European Organization for
Research and Treatment of Cancer Quality of Life (EORTC QOL)
(19) and the International Prostate Symptom Score (IPSS) (20)
before the start of the therapy, during the 3rd or 4th week, after
completion of therapy, and 3 and 6 months after it. Side-effects were
graded based on the Common Terminology Criteria for Adverse
Events (CTCAE, version 4.03) (21).
Statistical methods. Data were reported as mean±SD or median
values. Daily changes of rectal fullness were evaluated by the paired
samples t-test. Statistical analysis (double T-test) of the
questionnaires was made with IBM SPSS 20.0 (SPSS Inc., Chicago,
IL, USA). A p<0.05 was considered significant.
Results
Patient characteristics. A total of 55 patients with high risk
or locally advanced PC took part in the study. Mean age of
the patients was 65.60 (range=53.33-83.49 years) years. Most
of the patients were overweight, mean BMI was 26.96
(range=19.37-41.62kg/m2) kg/m2. The number of patients
with T2 stage was 41 (74.55%), T3 stage 12 (21.82%) and T4
stage 2 (3.64%). Gleason score was 7 in 27 (48.21%), while
8, 9 and 10 in 5 (9.09%), 19 (33.93%) and 4 (7.14%) cases,
respectively. Initial PSA level was lower than 10 ng/ml and
was between 10 and 20 ng/ml in 13 (23.21%) and in 9
(16.36%) cases, respectively. In case of 33 (58.93%) patients
the initial PSA level was ≥20 ng/ml. A total of 52 (94.55%)
patients received the whole prescribed dose (77 Gy). RT had
to be completed earlier in 3(5.45%) cases (74 Gy) due to
necessity of a urinary catheter during treatment.
Determination of safety margins. CTV-PTV safety margins
were the following: lateral: 4.44 mm, longitudinal: 9.69 mm,
vertical: 4.98 mm (Table I). 
Daily evaluation of the rectal fullness. The data of mean AP,
LAT and OBL diameters in the upper and lower area of the
symphysis on the topometric CT rather than during the
therapy on the CBCT in the same region and the daily
alterations of treatment time are recorded in Table II. In the
upper area of the symphysis the diameters of the rectal wall
were significantly different, but in the lower area of the
symphysis - in the region of the prostate - no significant
differences were detected (Figure 1).
Side-effects and quality of life. The most common acute side-
effects were cysto-urethritis and radiation induced enteritis-
proctitis. Almost half and a quarter of the patients complained
of GU and GI side-effects, respectively. Temporary urinary
catheter was needed in 3 patients. Almost all patients had hot
flashes and erectile dysfunction of different grade, but only
40% of them experienced significant complaints. Median
(range) period of follow-up was 6 months (range=3-12
months). The most important acute and late (3 and 6 months)
side-effects are shown in Figure 2. Based on the EORTC
QOL, urination and defecation were significantly worse during
the therapy than before. These complaints improved
significantly after 3 and 6 months. Erectile dysfunction was
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detected in more than one third of patients initially and this
rate decreased during the radiotherapy. Evaluation of the
patients’ sexual life was quite difficult because psychological
factors may influence the patients’ answers and erectile
function can be also worsened by ADT. 
Based on total evaluation of the EORTC QOL, the patients’
quality of life did not change significantly during therapy,
although significant improvements could be detected in 3 and
6 months after therapy (Figure 3). Scores of IPSS questionnaire
regarding quality of life were similar to these data, such as
prostate specific symptoms: no significant worsening could be
detected during the therapy; however significant improvements
were registered during the follow-up visits (Figure 4).
Discussion
During the last 20 years many prospective randomized
clinical studies have proven that local dose escalation
significantly improves biochemical control (3, 4, 5). Despite
the elevated dose in the target volume, the dose of OARs can
be reduced without increased toxicity, using modern RT (7,
8), positioning and immobilization techniques (9-13).
Zelefsky et al. (13) and McLaughlin et al. (14) have found
that significantly lower doses can be administered to the
rectum in prone position, but they could not confirm it in the
case of urinary bladder. This may be explained by the fact that
planning was made with empty urinary bladder and it can be
improved by planning and treating with a full bladder, so one
part of the bladder can move away from the target volume. 
Radiation exposure of intestines is better in prone position
with the use of BB, than in supine position, in case of 3D-CRT
and IMRT technique, which may decrease the GI morbidity in
itself (9). Gonzalez et al. (10) found that a significantly smaller
volume of the small intestine receives more than 20 Gy dose
in prone position with the use of BB, while the interfraction
dose variation to the small bowel was similar to the supine
position. Bajon et al. (11) have shown decreased dose exposure
of the urinary bladder in prone position besides sparing the
rectum and the small intestine. Chen et al. (22) have studied
the daily change of the rectal and urinary bladder volume of
19 patients and 314 CBCT pictures. Therapy was administered
in supine position with full bladder. 
With the use of IG-IMRT patient setting errors can be
eliminated, so accuracy of spatial dose delivering can be
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Table I. Determination of safety margins.
Number of patients: 55
Number of examinations: 652
                                                     Vertical (cm)                        Longitudinal (cm)                              Lateral (cm)                           3D vectorial (cm)
Random error                                    0.3249                                       0.6870                                            0.2862                                         0.4495
Systematic error                                0.1086                                       0.1955                                            0.0995                                         0.1674
CTV-PTV margin                             0.4987                                       0.9695                                            0.4491                                         0.7332
CTV: Clinical target volume; PTV: planning target volume.
Table II. Analysis of rectal diameter’ daily alteration during treatment. Mean difference was counted from the mean results on topometric CT minus
the mean results of cone beam CT. In the upper area of the symphysis the diameters of the rectal wall were significantly different, but in the lower
area of the symphysis – in the region of the prostate there – could not any significant difference detected.
Diameters of rectum                            Mean results on       Mean diff.                      SD                        95%CI of the difference                   p-Value
                                                                   TCT (cm)                  (cm)
                                                                                                                                                                    Lower                     Upper                         
Upper area of the symphysis
   AP                                                               4.36                     0.169                          0.407                      0.059                      0.279                    0.003
   LAT                                                             3.95                     0.193                          0.578                      0.037                      0.349                    0.016
   OBL                                                            4.12                     0.107                          0.339                      0.016                      0.199                    0.023
Lower area of the symphysis
   AP                                                               2.80                     0.018                          0.112                    –0.012                      0.048                    0.239
   LAT                                                             2.58                   –0.007                          0.106                    –0.036                      0.021                    0.621
   OBL                                                            2.67                     0.029                          0.227                    –0.032                      0.090                    0.347
AP: Anteroposterior; LAT: lateral; OBL: oblique; TCT: topometric computer tomography; diff.: difference; SD: standard deviation; CI: confidence
interval.
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Figure 1. Continued
increased, that may lead to improved clinical results (23). In
case of prostate cancer patients, the extent of radiotherapy safety
zone (CTV-PTV margin) is being studied (recommendations are
available from 1 mm to 10 mm) (8). Determination of the
proper safety zone has to be estimated by the different
institutions taking local conditions into consideration. It can be
decreased by marking and mask fixation. For further decrease
of the safety zone, besides the precise patient positioning and
daily IGRT, the transperineal gold marker implantation was
introduced according to Jorgo et al. (24).
As the technique of radiotherapy has improved and
patient’s overall survival has increased, the incidence of side-
effects and the way they influence the patients’ QOL became
important (3, 4). Acute side-effects (mainly cysto-urethritis
and radiation induced enteritis-proctitis) develop during
radiotherapy (usually from the 6th week) and cease on the
first follow-up visit after therapy (2-3 months). Late
toxicities usually develop 90 days after completion of
radiotherapy and include: chronic cystitis, incontinence,
urethral stricture, chronic proctitis and rectal bleeding. In
2007 Dearnaley et al. (4) compared side-effects of 64 Gy and
74 Gy dose escalation. Mainly acute and late GI side-effects
occurred but were not significant. Late GU side-effects were
also common, but there were no significant increases in
toxicity frequency and grade. In 2011, Beckendorf et al. (3)
published the 5-year follow-up study of 70 Gy contra 80 Gy
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Figure 1. Rectal diameter alteration in the upper and lower area of the symphysis.
Figure 2. The most important acute and late (3 and 6 months) genitourinary (GU) and gastrointestinal (GI) side-effects.
dose escalations: better 5-year biochemical relapse-free
survival was detected in case of high-dose RT. Side-effects
were similar in the two arms, however higher proportion of
rectal (proctitis, rectal bleeding) and urinary (cystitis,
haematuria, urinary obstruction) toxicities were detected in
the 80 Gy group. In 2017, Sasaki et al. (25) published their
long-term outcomes of the effect of fraction dose reduction
(2.2 Gy to 2 Gy/fraction) to late GI toxicity by using helical
tomotherapy and IM-IGRT. They found that the reduced dose
fraction schedule decreased the incidence of late GI toxicity
without compromising prostate-specific antigen control. 
The limitation of this study is its relatively small number
of patients. Regarding the daily reconstruction of the rectum
and the accurate patient repositioning on a belly board,
further investigations are needed. The late toxicities
developed and the quality of life after pelvic IMRT for
prostate cancer are under further examination.
Conclusion
IMRT radiotherapy in the prone position can be properly
carried out in case of high risk PC patients. Using belly
board and mask fixation, vertical and lateral setting accuracy
detected with CBCT is similar to the literature. GU/GI side-
effects of this therapy were tolerable. Change of patients’
quality of life is insignificant during RT, while improvement
3 and 6 months after RT may be due to rapid recovery from
side-effects and effectiveness of therapy.
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